In keeping with such a postulate, we observed the bromocriptine reversal of metabolic syndrome in animal models of metabolic syndrome having normal to low plasma prolactin levels such as ob/ob and db/db mice [128,129], and even in animals with diminished α-melanocyte stimulating hormone (αMSH)–melanocortin-4 receptor activation [130], as have others more recently [131]. The gene discussed is STAMBP; the disease is metabolic syndrome.